>Marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique, par classe (classe 1 - protéines effectrices multiples et classe 2 - protéine de liaison unique à l'ARNrCr), produits et services (produits et services), application (diagnostic biomédical, ingénierie génomique , découverte de médicaments, applications agricoles et autres), flux de travail (préparation d'échantillons, préamplification, ARNrCr, enzymes Cas et détection), utilisateur final ( hôpitaux , centres de diagnostic, sociétés de biotechnologie, instituts universitaires et de recherche et autres), canal de distribution (appel d'offres direct, ventes au détail) Tendances et prévisions de l'industrie jusqu'en 2029
Définition et perspectives du marché
CRISPR est un ensemble de courtes répétitions palindromiques régulièrement espacées. C'est un outil d'édition du génome qui permet aux chercheurs de modifier facilement les séquences d'ADN et de modifier la fonction des gènes. Il a de nombreuses applications potentielles, notamment la correction des défauts génétiques et le traitement et la prévention de la propagation des maladies. Les diagnostics basés sur CRISPR ont été utilisés pour de nombreuses applications biomédicales, telles que la détection de biomarqueurs à base d'acide nucléique de maladies infectieuses et non infectieuses et la détection de maladies génétiques. Les kits d'analyse de CRISPR sont composés de deux composants : une protéine appelée Cas9 et un ARN guide, une chaîne de molécules d'acide nucléique avec un certain code génétique.
Ce système CRISPR-Cas9 a été modifié pour être utilisé dans les cellules de mammifères. Nous pouvons soit éliminer des gènes spécifiques en introduisant une séquence guide (sgRNA) spécifique à notre gène d'intérêt en introduisant des mutations par décalage de cadre via la jonction d'extrémités non homologues (NHEJ), soit générer des mutations par knock-in.
Les systèmes CRISPR-Cas 9 ont élargi le champ d'application des diagnostics et des services dans le domaine des thérapies géniques et cellulaires. Les sociétés pharmaceutiques investissent massivement dans la R&D pour développer de nouveaux produits, avec une augmentation du nombre d'agents de thérapie génique et cellulaire entrant dans les premières phases de développement. Les investissements des acteurs du marché permettraient de produire des traitements sûrs et efficaces pour les patients qui en ont sérieusement besoin.
La détection et le diagnostic des gènes CRISPR en Asie-Pacifique sont favorables et visent à réduire la gravité des symptômes. Data Bridge Market Research analyse que le marché de la détection et du diagnostic des gènes CRISPR connaîtra un TCAC de 21,6 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par classe (Classe 1 - Protéines effectrices multiples et Classe 2 - Protéine de liaison unique à l'ARNrCr), Produits et services (Produits et services.), Application (Diagnostics biomédicaux, Ingénierie du génome, Découverte de médicaments, Applications agricoles et autres.), Flux de travail (Préparation d'échantillons, Préamplification, ARNrCr, Enzymes Cas et détection.), Utilisateur final (Hôpitaux, Centres de diagnostic, Sociétés de biotechnologie, Instituts universitaires et de recherche et autres) Canal de distribution (Appel d'offres direct, Ventes au détail), |
|
Pays couverts |
China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines And Rest Of Asia-Pacific |
|
Market Players Covered |
GenScript, Takara Bio Inc., OriGene Technologies, Inc., Agilent Technologies, Inc., Synthego, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher) Thermo Fisher Scientific Inc. among others. |
Asia-Pacific CRISPR Gene Detection and Diagnostic Market Dynamics
Drivers
- Rise in prevalence and incidence of chronic diseases
Chronic diseases are common health conditions, where one in three the adults suffer from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens.
CRISPR is abbreviated as clustered regularly interspaced short palindromic repeats. In recent years, CRISPR has become a commanding tool for gene editing, which is used to alter the specific sequences of DNA in a cell. CRISPR has important use in the research and treatment of Huntington’s disease, muscular dystrophy, cancer and high cholesterol.
For instance,
- In 2021, the data by NORD - National Organization for Rare Disorders, Inc. stated the diagnosed incidence of Duchenne Muscular Dystrophy (DMD). The Duchenne Muscular Dystrophy (DMD) is a frequent genetic condition, which affects 1 in 3,500 male births worldwide
- Rise In Investment In Research And Development
Gene editing technologies, such as the CRISPR-Cas 9 system, have extended the scope of diagnostics and services in gene and cell therapies. Pharmaceutical companies invest heavily in R&D to develop new products, with a surge of gene and cell therapy agents entering early development. The market players investing would allow to achieve the goal of producing safe and effective treatments for patients in serious need.
For instance,
- In February 2022, Synthego had raised USD 200 million as an investment for research and development to boost the development of CRISPR-Based Medicines from early-phase research to the clinic. Synthego will use the investment amount from Series E finance to accelerate the creation of CRISPR diagnostics and services
Availability of funding for CRISPR gene diagnostics
CRISPR gene diagnostics and research are funded by the National Institute of Health (NIH) budget. The private sector also funds the CRISPR gene detection and research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With genome editing being such a new field, an unbiased governmental body must supervise them; the FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries., will further enhance the growth of the CRISPR gene detection and diagnostic market.
Furthermore, advancement in CRISPR gene diagnostics, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the Asia-Pacific CRISPR gene detection market. Other factors such as increase in the demand for effective therapies and rising awareness about the timely diagnosis and will positively impact the CRISPR gene detection and diagnostic market's growth rate. Additionally, high disposable income, rising number of chronic diseases, changing lifestyle will result in the expansion of the CRISPR gene detection and diagnostic market.
Opportunities
- The rise in healthcare expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.
- Strategic initiative by market players
The demand for CRISPR gene detection and diagnosis has increased the demand in the U.S. and Asia-Pacific owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
For instance,
- In May 2021, Horizon Discovery Ltd. extended the gene modulation portfolio with the first synthetic single guide RNA and patent pending dcas9 repressor for CRISPR interference in Waltham. The expansion of the portfolio had increased the sales and revenue of the synthetic guide RNA portfolio across the U.S. and the U.K. region and had increased the collaboration with market players
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the CRISPR gene detection and diagnostic market in the forecast period of 2022-2029. Also, high unmet need of current and developments in healthcare technology will escalate the growth rate of the CRISPR gene detection and diagnostic market in future.
Restraints/Challenges
However, high cost of CRISPR diagnostics and risks faced while using the CRISPR diagnostics will impede the growth rate of CRISPR gene detection and diagnostic market. Additionally, the risks incurred while using the MRI devices will hinder the CRISPR gene detection and diagnostic market growth. The lack of skilled expertise and regulations will further challenge the market in the forecast period mentioned above.
- Rise in cost of CRISPR based diagnostics
The vast potential of CRISPR based therapeutics comes with a cost tag. Maximum genome editing therapies require an increased amount of time for development and production, and hence the rise in cost occurs. Besides, the assay kits and medications related to CRISPR gene detection and diagnostic are applicable to large section of population. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend in the future.
For instance,
- In July 2021, according to Integrated DNA Technologies, Inc., the first commercially available CRISPR-based diagnostic assay for SARS-CoV-2 including reverse transcription LAMP (RT-LAMP) as preamplification is currently available at USD 30.15 per reaction
The CRISPR gene detection and diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on CRISPR gene detection and diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to a study by Globocan. In 2020, breast cancer had high incidence of cases, around 11.7%, followed by lung cancer which is 11.40%, colorectum cancer which is 10.00%, and cervix uteri and oesophagus cancer having less number of incident cases.
CRISPR gene detection and diagnostic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on the CRISPR Gene Detection and Diagnostic Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- En août 2020, SHERLOCK BIOSCIENCES a annoncé une collaboration avec Dartmouth-Hitchcock Health pour mener l'essai clinique du kit de diagnostic SHERLOCK pour le Sars-CoV-2. Le kit a reçu l'approbation d'urgence de l'autorisation d'utilisation d'urgence (EUA) de la Food and Drug Administration (FDA) des États-Unis.
Portée du marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique
Le marché de la détection et du diagnostic des gènes CRISPR est segmenté en six segments : classe, produits et services, application, flux de travail, utilisateur final et canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance faibles dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Classe
- Classe 1 – Protéines à effecteurs multiples
- Classe 2 - Protéine de liaison à un seul ARNr
Sur la base de la classe, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en classe 1 - protéines effectrices multiples et classe 2 - protéine de liaison CrRNA unique.
Produits et services
- Produits
- Services
Sur la base des produits et services, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en produits et services.
Application
- Diagnostic biomédical
- Ingénierie génomique
- Découverte de médicaments
- Applications agricoles
- Autres
Sur la base des applications, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en diagnostics biomédicaux, ingénierie du génome, découverte de médicaments, applications agricoles et autres.
Flux de travail
- Préparation des échantillons
- Pré-amplification
- ARNr
- Enzymes Cas
- Détection
Sur la base du flux de travail, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en préparation d'échantillons, préamplification, CrRNA, enzymes Cas et détection.
Utilisateur final
- Hôpitaux
- Centres de diagnostic
- Sociétés de biotechnologie
- Instituts universitaires et de recherche
- Autres
Sur la base de l'utilisateur final, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en hôpitaux, centres de diagnostic, sociétés de biotechnologie, instituts universitaires et de recherche et autres.
Canal de distribution
- Appels d'offres directs
- Ventes au détail
Sur la base du canal de distribution, le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est segmenté en appels d’offres directs et ventes au détail.
Analyse/perspectives régionales du marché de la détection et du diagnostic des gènes CRISPR
Le marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique est analysé et des informations et tendances sur la taille du marché sont fournies par régions, classe, produits et services, application, flux de travail, utilisateur final et canal de distribution comme référencé ci-dessus.
Les pays couverts dans le rapport sur le marché de la détection et du diagnostic des gènes CRISPR sont la Chine, le Japon, la Corée du Sud, l’Inde, l’Australie, Singapour, la Thaïlande, la Malaisie, l’Indonésie, les Philippines et le reste de l’Asie-Pacifique.
La Chine domine le marché de la détection et du diagnostic des gènes CRISPR en raison de l’augmentation des essais cliniques pour les diagnostics basés sur CRISPR.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du diagnostic et de la détection des gènes CRISPR
Le paysage concurrentiel du marché de la détection et du diagnostic des gènes CRISPR en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché de la détection et du diagnostic des gènes CRISPR.
Certains des principaux acteurs opérant sur le marché de la détection et du diagnostic de gènes CRISPR sont GenScript, Takara Bio Inc., OriGene Technologies, Inc., Agilent Technologies, Inc., Synthego, Merck KGaA, Integrated DNA Technologies, Inc. (Une filiale de Danaher) Thermo Fisher Scientific Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE)
6 EPIDEMIOLOGY
7 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO
8 PIPELINE ANALYSIS FOR ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS
9.2 RESTRAINTS
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH
9.2.4 AVAILABILITY OF ALTERNATIVES
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
9.3.2 RISE IN HEALTHCARE EXPENDITURE
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS
9.4 CHALLENGES
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS
9.4.2 STRINGENT REGULATIONS
10 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS
10.1 OVERVIEW
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN
10.2.1 BIOMEDICAL DIAGNOSTICS
10.2.2 AGRICULTURAL APPLICATIONS
10.2.3 GENOME ENGINEERING
10.2.4 DRUG DISCOVERY
10.2.5 OTHERS
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS
11 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES
11.1 OVERVIEW
11.2 PRODUCTS
11.2.1 ASSAY KITS
11.2.1.1 SGRNA KIT
11.2.1.2 GENOMIC DETECTION KIT
11.2.1.3 OTHERS
11.2.2 PROTEINS
11.2.2.1 CAS9
11.2.2.2 CPF1
11.2.2.3 OTHERS
11.2.3 PLASMID AND VECTOR
11.2.4 LIBRARY
11.2.5 CONTROL KITS
11.2.6 DELIVERY SYSTEM PRODUCTS
11.2.7 DESIGN TOOLS
11.2.8 GENOMIC RNA
11.2.9 HDR BLOCKERS
11.2.9.1 AZIDOTHYMIDINE
11.2.9.2 TRIFLUOROTHYMIDINE
11.2.9.3 OTHERS
11.2.9.4 OTHERS
11.3 SERVICES
11.3.1 G-RNA DESIGN
11.3.2 CELL LINE ENGINEERING
11.3.3 MICROBIAL GENE EDITING
11.3.4 DNA SYNTHESIS
11.3.5 OTHERS
12 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 BIOMEDICAL DIAGNOSTICS
12.2.1 CANCER
12.2.2 BLOOD DISORDERS
12.2.3 HEREDITARY DISORDERS
12.2.4 MUSCULAR DYSTROPHY
12.2.5 AIDS
12.2.6 NEURODEGENERATIVE CONDITION
12.2.7 OTHERS
12.3 AGRICULTURAL APPLICATIONS
12.4 GENOME ENGINEERING
12.4.1 CELL LINE ENGINEERING
12.4.2 HUMAN STEM CELLS
12.5 DRUG DISCOVERY
12.6 OTHERS
13 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW
13.1 OVERVIEW
13.2 CRRNA
13.3 CAS ENZYME
13.4 PRE-AMPLIFICATION
13.4.1 PCR
13.4.2 LAMP
13.4.3 RPA
13.5 SAMPLE PREPARATION
13.6 SENSING
13.6.1 FLUORESCENT PROBES
13.6.2 COLORIMETRIC
14 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER
14.1 OVERVIEW
14.2 BIOTECHNOLOGY COMPANIES
14.3 ACADEMIC AND RESEARCH INSTITUTES
14.4 DIAGNOSTIC CENTERS
14.5 HOSPITALS
14.6 OTHERS
15 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
16 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 INDIA
16.1.4 SOUTH KOREA
16.1.5 AUSTRALIA
16.1.6 SINGAPORE
16.1.7 THAILAND
16.1.8 PHILIPPINES
16.1.9 MALAYSIA
16.1.10 INDONESIA
16.1.11 REST OF ASIA-PACIFIC
17 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 THERMO FISHER SCIENTIFIC INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 MERCK KGA
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 AGILENT TECHNILOGIES, INC
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 GENSCRIPT
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 10 X GENOMICS
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 APPLIED STEM CELL
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 ADDGENE
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOVISION INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CELLECTA, INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 CAS TAG BIOSCIENCES
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 GENECOPOEIA, INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HORIZON DISCOVERY LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HERA BIOLABS
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 NEW ENGLAND BIOLABS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 ORIGENE TECHNOLOGIES, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SYNTHEGO
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TAKARA BIO INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 TOOLGEN, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE ANALYSIS FOR ASIA PACIFIC CRISPR GENE THERAPEUTICS
TABLE 2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC CLASS-1 MULTIPLE EFFECTOR PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC AGRICULTURAL APPLICATIONS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC DRUG DISCOVERYIN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC CRRNA IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC CAS ENZYME IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC SAMPLE PREPARATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC BIOTECHNOLOGY COMPANIES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC DIAGNOSTIC CENTERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC HOSPITALS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC DIRECT TENDER IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC RETAIL SALES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 53 ASIA-PACIFIC SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 54 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 57 CHINA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 59 CHINA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 62 CHINA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 63 CHINA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 CHINA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 CHINA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 68 CHINA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 69 CHINA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 70 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 73 JAPAN CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 75 JAPAN PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 JAPAN ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 77 JAPAN HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 78 JAPAN PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 79 JAPAN SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 JAPAN GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 JAPAN BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 84 JAPAN PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 85 JAPAN SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 86 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 87 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 89 INDIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 90 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 91 INDIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 INDIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 93 INDIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 94 INDIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 95 INDIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 97 INDIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 INDIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 99 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 100 INDIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 101 INDIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 102 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 105 SOUTH KOREA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 107 SOUTH KOREA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 SOUTH KOREA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 109 SOUTH KOREA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 110 SOUTH KOREA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 SOUTH KOREA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 SOUTH KOREA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 114 SOUTH KOREA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 116 SOUTH KOREA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 117 SOUTH KOREA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 118 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 122 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 123 AUSTRALIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 AUSTRALIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 125 AUSTRALIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 126 AUSTRALIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 127 AUSTRALIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 129 AUSTRALIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 130 AUSTRALIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 132 AUSTRALIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 133 AUSTRALIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 134 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 137 SINGAPORE CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 138 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 139 SINGAPORE PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 SINGAPORE ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 141 SINGAPORE HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 142 SINGAPORE PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 143 SINGAPORE SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 SINGAPORE GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 SINGAPORE BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 148 SINGAPORE PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 149 SINGAPORE SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 150 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 151 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 152 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 153 THAILAND CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 155 THAILAND PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 THAILAND ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 158 THAILAND PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 159 THAILAND SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 161 THAILAND GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 162 THAILAND BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 163 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 164 THAILAND PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 165 THAILAND SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 166 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 167 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 168 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 169 PHILIPPINES CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 170 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 171 PHILIPPINES PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 PHILIPPINES ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 173 PHILIPPINES HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 174 PHILIPPINES PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 175 PHILIPPINES SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 177 PHILIPPINES GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 178 PHILIPPINES BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 179 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 180 PHILIPPINES PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 181 PHILIPPINES SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 182 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 183 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 184 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 185 MALAYSIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 186 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 187 MALAYSIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 MALAYSIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 189 MALAYSIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 190 MALAYSIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 191 MALAYSIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 193 MALAYSIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 194 MALAYSIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 195 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 196 MALAYSIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 197 MALAYSIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 198 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 199 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 200 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 201 INDONESIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 202 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 203 INDONESIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 INDONESIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 205 INDONESIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 206 INDONESIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 207 INDONESIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 209 INDONESIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 210 INDONESIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 211 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 212 INDONESIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 213 INDONESIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 214 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 215 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 216 REST OF ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN TECHNOLOGICAL ADVANCEMENTS IN CRISPR DIAGNOSTICS, AND GOVERNMENT FUNDING FOR THE DEVELOPMENT OF CRISPR DETECTION KITS ARE EXPECTED TO DRIVE THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 TO 2029
FIGURE 13 CLASS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 & 2029
FIGURE 14 ASIA PACIFIC CRISPR GENE PATENT SCENARIO, BY APPLICATION
FIGURE 15 CRISPR PATENT LANDSCAPE AND NUMBER OF APPLICATIONS OF NEW PATENT FAMILIES FILED WORLDWIDE, 2001 TO 2019
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET
FIGURE 17 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020
FIGURE 18 PREVALENCE OF HUNTINGTON’S DISEASE IN 2019
FIGURE 19 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2021
FIGURE 20 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2021
FIGURE 24 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2021
FIGURE 28 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2021
FIGURE 32 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2021
FIGURE 36 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SNAPSHOT (2021)
FIGURE 44 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021)
FIGURE 45 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS (2022 & 2029)
FIGURE 48 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
